Fresenius Medical Care AG

FME

Equity

ISIN DE0005785802 / Valor 520878

Xetra (2024-11-20)

EUR 40.80-2.23%

Fresenius Medical Care AG
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Fresenius Medical Care AG is a global leader in the provision of dialysis products and services, catering to approximately 4.1 million patients worldwide who require regular dialysis treatment. In addition to its core business in the Renal Care Continuum, the company is actively expanding into complementary areas and critical care. With a focus on dialysis machines, dialyzers, and other related products, Fresenius Medical Care AG is dedicated to meeting the needs of individuals with renal diseases.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2024, Fresenius Medical Care AG reported revenue of EUR 4,725 million, reflecting a 2% increase at constant currency and a 5% organic growth. The revenue growth was driven by both the Care Delivery and Care Enablement segments, with Care Delivery U.S. showing a notable increase due to a growing value-based care business and favorable reimbursement rates.

Operating Income

Fresenius Medical Care AG's operating income for Q1 2024 decreased by 6% to EUR 246 million, resulting in a margin of 5.2%. However, when adjusted for constant currency, special items, and the impacts of closed divestitures, the operating income increased by 23% to EUR 416 million, with a margin of 8.6%. This improvement was driven by positive pricing effects and savings from the FME25 program.

Net Income

Net income for Fresenius Medical Care AG in the first quarter of 2024 decreased by 18% to EUR 71 million. On an outlook base, which excludes special items and divestiture impacts, net income increased by 35%. Basic earnings per share (EPS) also saw a decrease of 18% to EUR 0.24, but on an outlook base, EPS increased by 35%.

Cash Flow

Fresenius Medical Care AG generated EUR 127 million in operating cash flow during Q1 2024, resulting in a margin of 2.7%. The operating cash flow was negatively impacted by EUR 58 million due to a cyber incident at Change Healthcare, a U.S. service provider. Free cash flow for the quarter amounted to EUR -2 million.

FY 2024 Outlook

Fresenius Medical Care AG confirmed its financial outlook for fiscal year 2024, expecting revenue to grow by a low- to mid-single digit percent rate and operating income to grow by a mid- to high-teens percent rate compared to the prior year. The company aims to achieve an operating income margin of 10% to 14% by 2025, excluding impacts from portfolio changes.

Summarized from source with an LLMView Source

Key figures

14.5%1Y

-26.9%3Y

-38.5%5Y

Performance

31.2%1Y

33.6%3Y

30.6%5Y

Volatility